Olympus 2005 Annual Report Download - page 48

Download and view the complete annual report

Please find page 48 of the 2005 Olympus annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 58

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58

46 O LYMPUS 2 00 5
Thousands of U.S. dollars
2005
Imaging Medical Life Information and Elimination
Systems Systems Science Co mmunication and Conso lidated
Business Business Business Business O thers Total Corporate Total
Net sales:
Unaffiliated customers............. $2,52 4,409 $2,09 5,682 $921,04 5 $1,48 4,073 $370,59 1 $7 ,395,800 $ $7 ,395,800
Intersegment ......................... 246 45 110 8 4 09 (409)
Total ....................................... 2,524 ,655 2 ,095,727 9 21,155 1,484,0 73 370,599 7,396,2 09 (409 ) 7,395,8 00
O perating expenses................... 2,741 ,700 1,502,036 860,21 0 1 ,493,500 3 87,272 6,984,7 18 200,60 0 7 ,185,318
O perating income (loss) ............. (217,045 ) 593,6 91 60,945 (9,42 7) (16,673) 4 11,491 (201,009 ) 210,4 82
Assets ..................................... 1 ,315,518 1 ,613,455 6 89,164 1,099,9 64 533,08 1 5,251,1 82 2,549 ,573 7,800,7 55
Depreciation and amortization .... 1 0 1,673 8 6,118 39,1 27 7 ,627 15,4 0 0 249,945 20,582 270,52 7
Capital expenditures.................. $ 1 45,336 $ 1 33,355 $ 56,3 1 8 $ 1 2,009 $ 15,837 $ 3 62,855 $ 56,481 $ 419,3 36
No te: These five business segments include the following products:
Imaging Systems Business: Film cameras, Digital cameras, Voice Recorders, Magneto-optical disk drives
Medical Systems Business: M edical endoscopes, Surgical endoscopes, Endo-therapy devices, Ultrasound endoscopes
Life Science Business: Diagnostic systems, Biological microscopes, Analytical services of genomic information, Industrial microscopes
Information and Communication Business: Mobile terminals, Mobile solutions, Mobile content services, N etwork infrastructure systems, System development,
Semiconductor devices, Electric equipment
O thers: Medical new business, Software development, Industrial endoscopes, Printers, Bar code data processing equipment,
Measuring equipment, etc.
(b) O n May 31, 2005, the Company acquired 1 0 0% of the shares outstanding of R/ D Tech Inc. (Québec, Canada) through its wholly owned
subsidiary, O lympus NDT Canada Inc. (Q uébec, Canada) for a total o f approximately 117 million Canadian dollars (approximately
¥10,100 million, US$91,818 thousand). Following the acquisition, the Company to ok in technology in the areas o f ultrasound defect
detectio n and eddy current defect detection. By integrating the advanced technologies of O lympus and R/ D Tech Inc., it will be possible
to create new value in the non-destructive testing (NDT) field. O lympus NDT Canada Inc. merged with R/ D Tech Inc. on May 31, 2005 .
The overview of R/ D Tech Inc., O lympus NDT Canada Inc. and company after the merger are as belo w.
1. R/ D Tech Inc.
(1) Trading name: R/ D Tech Inc.
(2) Representative: Alain Allard
(3) Address: 505, boul. du Parc-Technologique, Q uébec G1P 4 S9, Canada
(4) Principal activities: Development, manufacturing and sale of non-destructive testing equipment
(5) Common stock: CN$2,362,152
(6) Numbers of shares outstanding: 8 ,3 93,631
2. O lympus NDT Canada Inc.
(1) Trading name: O lympus NDT Canada Inc.
(2) Representative: Yasuo Yoda
(3) Address: 1000, de La Gauchetière Street West, Suite 2100, Mo ntréal, Q uébec H3B 4W 5, Canada
(4) Relationship to the Company: 100% subsidiary of the Company
3. Company after the merger
(1) Trading name: O lympus NDT Canada Inc.
(2) Representative: Toshihiko O kubo
(3) Address: 1000, de La Gauchetière Street West, Suite 2100, Mo ntréal, Q uébec H3B 4W 5, Canada
(4) Principal activities: Development, manufacturing and sale of non-destructive testing equipment
(5) Common stock: CN$20,000,001
(6) Numbers of shares outstanding: 1 0 1
(7) Relationship to the Company: 100% subsidiary of the Company
(c) At the general meeting held on June 29, 2 0 05, the shareholders appro ved a cash dividend totaling ¥1,978 millio n ($17,9 8 2 thousand)
or ¥7.50 ($0.0 7 ) per share. In accordance with the Code, the declaration o f this dividend has not been reflected in the accompanying
consolidated financial statements as of March 31, 200 5 .